Zhang Haonan, He Chengcheng, Guo Xuxue, Fang Yuxin, Lai Qiuhua, Wang Xinke, Pan Xingzhu, Li Haolin, Qin Kaiwen, Li Aimin, Liu Side, Li Qingyuan
Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Department of Gastroenterology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Cell Death Discov. 2022 Jan 19;8(1):30. doi: 10.1038/s41420-022-00827-7.
DDX39B (also called UAP56 or BAT1) which is a kind of DEAD-box family helicase plays pivotal roles in mRNA binding, splicing, and export. It has been found upregulated in many kinds of tumors as an oncogene. Nevertheless, the underlying molecular mechanisms of DDX39B in the proliferation of human colorectal cancer (CRC) remain fairly elusive. In our study, function experiments including the CCK8 and colony formation assay revealed that DDX39B facilitates CRC proliferation in vitro. DDX39B knockdown cells were administered for the orthotopic CRC tumor xenograft mouse model, after which tumor growth was monitored and immunohistochemistry (IHC) was performed to prove that DDX39B can also facilitates CRC proliferation in vivo. Flow cytometry demonstrated that DDX39B promotes the proliferation of CRC cells by driving the cell cycle from G0/G1 phase to the S phase. Mechanistically, RNA-binding protein immunoprecipitation-sequencing (RIP-seq) confirmed that DDX39B binds directly to the first exon of the CDK6/CCND1 pre-mRNA and upregulates their expression. Splicing experiments in vitro using a RT-PCR and gel electrophoresis assay confirmed that DDX39B promotes CDK6/CCND1 pre-mRNA splicing. Rescue experiments indicated that CDK6/CCND1 is a downstream effector of DDX39B-mediated CRC cell proliferation. Collectively, our results demonstrated that DDX39B and CDK6/CCND1 direct interactions serve as a CRC proliferation promoter, which can accelerate the G1/S phase transition to enhance CRC proliferation, and can offer novel and emerging treatment strategies targeting this cell proliferation-promoting gene.
DDX39B(也称为UAP56或BAT1)是一种DEAD-box家族解旋酶,在mRNA结合、剪接和输出过程中发挥着关键作用。研究发现,作为一种癌基因,它在多种肿瘤中表达上调。然而,DDX39B在人类结直肠癌(CRC)增殖中的潜在分子机制仍相当不清楚。在我们的研究中,包括CCK8和集落形成试验在内的功能实验表明,DDX39B在体外促进CRC增殖。将DDX39B敲低的细胞用于原位CRC肿瘤异种移植小鼠模型,然后监测肿瘤生长并进行免疫组织化学(IHC)检测,以证明DDX39B在体内也能促进CRC增殖。流式细胞术表明,DDX39B通过推动细胞周期从G0/G1期进入S期来促进CRC细胞增殖。机制上,RNA结合蛋白免疫沉淀测序(RIP-seq)证实DDX39B直接与CDK6/CCND1前体mRNA的第一个外显子结合并上调其表达。使用RT-PCR和凝胶电泳分析进行的体外剪接实验证实DDX39B促进CDK6/CCND1前体mRNA剪接。挽救实验表明,CDK6/CCND1是DDX39B介导的CRC细胞增殖的下游效应因子。总的来说,我们的结果表明,DDX39B与CDK6/CCND1的直接相互作用作为CRC增殖的促进因子,可加速G1/S期转换以增强CRC增殖,并可为靶向这种促进细胞增殖基因的新型治疗策略提供依据。